New Post: Zolgensma Tumour Risk: Does the Gene Therapy Cause Tumours? lifesciencedaily.news/zolgen…
A small beverage maker sometimes typed the same data into its spreadsheets five or six times. Then Saint Louis University business students got hold of its order book. lifesciencedaily.news/univer… #SupplyChain #Manufacturing
Pathogen-reduced red blood cells held up against conventional ones in Cerus’s Phase 3 RedeS trial. The efficacy result isn’t the only finding in the release. lifesciencedaily.news/clinic… #ClinicalTrials #TransfusionMedicine
New Post: AI in Drug Discovery Is Great. Don’t Forget About AI in Drug Development lifesciencedaily.news/ai-dru…
New Post: MariTide Approval: When Could Amgen’s Obesity Drug Reach Patients? lifesciencedaily.news/mariti…
New Post: In Vivo CAR-T Is Shifting the Engineering Challenge Into Delivery lifesciencedaily.news/in-viv…
The only rationale on record for the AbbVie Nxera deal so far comes from Nxera. No AbbVie quote in the release, and no separate statement we could find as of 4 November. So what does $100 million upfront buy? lifesciencedaily.news/abbvie… #IBD #Biotech
Merck expects Keytruda to face US government price setting from 2029, and US sales to decline materially after that. It still sees 2027 as “another year of investment”. Our read of pharma Q3 earnings: lifesciencedaily.news/pharma… #PharmaEarnings
New Post: Preservative-Free Is Not Risk-Free: The Microbiology Behind Safe Cosmetics lifesciencedaily.news/preser…
New Post: COMP360 Approval: When Could Compass’s Psilocybin Be Cleared? lifesciencedaily.news/comp36…
New Post: What Happens After a Digital Mental Health Screening Result lifesciencedaily.news/mental…
New Post: Rethinking Biologics Plants to Earn Attractive Returns lifesciencedaily.news/proces…
New Post: BioMarin Fabry Deal: What Does It Get for $70 Million Upfront? lifesciencedaily.news/biomar…
New Post: The Fifty-Year Chase: Where Noninvasive Glucose Monitoring Stands in 2026 lifesciencedaily.news/noninv…
Note the time: 12:00 pm ET on Saturday 14 November. That is when the ObesityWeek embargo on accepted abstracts ends, unless otherwise specified. Our preview sets out what is on the programme. lifesciencedaily.news/obesit… #ObesityWeek
Without standard workflows, a vesicle biomarker signature found in one lab may be hard to reproduce elsewhere. A contributed piece from Creative Biolabs on what that means for neurology. lifesciencedaily.news/extrac… #ExtracellularVesicles #Neurology
New Post: BBP-418 Approval: When Could BridgeBio’s First LGMD Drug Launch? lifesciencedaily.news/bbp-41…
A generated traceability link doesn’t show the requirement behind it is correct. On AI-drafted medical device requirements, a contributor argues that judgement stays with engineers and clinicians. lifesciencedaily.news/ai-gen… #MedTech #SystemsEngineering
Eye health start-ups with a Southern California link can apply until 30 November for a funded six-month wet-lab bench from University Lab Partners, with @BauschLomb and the Gavin Herbert Eye Institute as partners. lifesciencedaily.news/founde… #Ophthalmology



















